

Questions for the Pediatric Advisory Committee
for November 18th, 2005.

1. FDA is proposing that it continue to monitor pediatric adverse events that are being reported for Tamiflu and return to the PAC with an additional report within the next 2 years.
 - Does the committee agree with this proposal?
 - Does the Committee have any comments about this proposal?

2. FDA will propose additional information for the Tamiflu labeling regarding serious skin reactions. Does the Committee agree with this approach?